The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.

Daniel V O'HaraThomas R ParkhillSunil V Badve Min Jun Meg J Jardine Vlado Perkovic

Published in: Diabetes, obesity & metabolism (2020)

Dipeptidyl peptidase-4 inhibitors are associated with a greater decline in eGFR, despite reducing the development and progression of albuminuria, and have no clear effect on other key kidney outcomes.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
glycemic control
insulin resistance
weight loss